Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2026
Prognostic factors of survival in corticobasal syndrome and corticobasal degeneration: A scoping review.
СтатьяScoping ReviewНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Saim Muhammad S, Al-Kazzaz Hayder, Ahmad Haris
Аннотация
BACKGROUND: Corticobasal syndrome (CBS) and corticobasal degeneration (CBD) are rare, progressive neurodegenerative disorders characterized by significant clinical and pathological heterogeneity. Although considerable research has addressed their diagnostic challenges, survival outcomes and prognostic factors remain poorly understood.
OBJECTIVE: To synthesize existing evidence on survival duration, mortality outcomes, and prognostic indicators in CBS and CBD.
METHODS: A scoping review was conducted following PRISMA-ScR guidelines across five databases, resulting in 36 studies meeting inclusion criteria. Data were extracted on demographics, disease duration, age at death, cause of death, clinical presentation, imaging biomarkers, genetic findings, and treatment-related outcomes.
RESULTS: The average disease duration for CBS and CBD ranged from 4 to 8 years, with age at death typically between 68 and 73 years. Pneumonia was the most common cause of death. Early presence of motor features, such as dystonia, apraxia, myoclonus, and alien limb, was consistently associated with shorter survival. On the other hand, cognitive impairment, age at onset, and sex were not reliably linked to prognosis. Imaging and biomarker findings were mixed, though recent studies suggest functional connectivity and midbrain atrophy may hold predictive value. The presence of dysphagia, earlier tube feeding, and bedridden state were associated with worse outcomes. Palliative interventions, including gastrostomy, may prolong survival when applied early.
CONCLUSION: Prognosis in CBS and CBD is shaped by specific motor and functional features, but many presumed indicators show inconsistent associations with survival. Future prospective studies are needed to improve prognostic accuracy and optimize care strategies, including timely palliative support.
OBJECTIVE: To synthesize existing evidence on survival duration, mortality outcomes, and prognostic indicators in CBS and CBD.
METHODS: A scoping review was conducted following PRISMA-ScR guidelines across five databases, resulting in 36 studies meeting inclusion criteria. Data were extracted on demographics, disease duration, age at death, cause of death, clinical presentation, imaging biomarkers, genetic findings, and treatment-related outcomes.
RESULTS: The average disease duration for CBS and CBD ranged from 4 to 8 years, with age at death typically between 68 and 73 years. Pneumonia was the most common cause of death. Early presence of motor features, such as dystonia, apraxia, myoclonus, and alien limb, was consistently associated with shorter survival. On the other hand, cognitive impairment, age at onset, and sex were not reliably linked to prognosis. Imaging and biomarker findings were mixed, though recent studies suggest functional connectivity and midbrain atrophy may hold predictive value. The presence of dysphagia, earlier tube feeding, and bedridden state were associated with worse outcomes. Palliative interventions, including gastrostomy, may prolong survival when applied early.
CONCLUSION: Prognosis in CBS and CBD is shaped by specific motor and functional features, but many presumed indicators show inconsistent associations with survival. Future prospective studies are needed to improve prognostic accuracy and optimize care strategies, including timely palliative support.